PrOSPeCT offers no-cost profiling for eligible Australians
Fortrea and Omico announced a collaboration to accelerate precision oncology research in Australia by helping connect cancer patients to biomarker-matched clinical trials. Fortrea, which sells clinical development solutions including phase I-IV clinical trial management, clinical pharmacology and consulting services, said the work will combine its oncology drug development experience with Omico’s Precision Oncology Screening Platform Enabling Clinical Trials program, known as PrOSPeCT.
By combining Omico’s precision oncology network with Fortrea’s scientific and clinical trial experience, the joint effort aims to improve study planning, site selection and patient recruitment. It also aims to expand access to biomarker-driven oncology research globally.
In Australia, Omico will support Fortrea’s clients with patient population insights, including genomic profiling, trial-matching capabilities, real-world oncology data and patient referral pathways. The collaboration will combine Fortrea’s oncology drug development experience with Omico’s flagship PrOSPeCT program.
PrOSPeCT is described as Australia’s largest precision oncology initiative and the largest cancer genomics initiative in the country. It is designed to provide molecular profiling and help match patients to biomarker-driven clinical trials and targeted therapies.
Eligible Australians can access molecular profiling and matching to biomarker-led clinical trials and therapies through PrOSPeCT at no cost to the patient. Omico and a national network of healthcare, research and industry partners deliver the program. It also generates clinical, genomic, treatment and outcomes data to advance research, improve cancer care and inform future health policy.
Omico cites national patient and clinician network
Omico said it has built one of Australia’s most extensive precision oncology ecosystems, combining molecular profiling, real-world evidence, cohort research programs and a nationwide network of investigators and clinical sites. The organisation has reported more than 23,000 consented patients within its clinic-genomic databases and referrals from more than 1,600 clinicians across Australia.
Omico is an independent, national, not-for-profit research organisation. It says it works with Australia’s leading cancer institutes, researchers, clinicians, industry partners, advocacy groups and government. Omico also says it works to improve outcomes for Australians with cancer through equitable access to precision oncology, translation of scientific advances into clinical care and research. Evidence generation to inform health policy and system reform.
“Our collaboration with Omico is about seeking to reach the right patient for the right study as quickly as possible,” said Oren Cohen, M.D., chief medical officer at Fortrea.
Cohen said modern oncology development demands greater precision to match specific cancers with therapies most likely to benefit patients. He added that the Omico partnership would help Fortrea identify patients for biomarker-driven studies in Australia and advance precision medicine for people with cancer.
Professor David Thomas, chief science and strategy officer at Omico, said Australia is well positioned to support global biomarker-driven clinical trials through the group’s national precision oncology research infrastructure, expertise and networks. He said combining Omico’s national data and trial-matching capabilities with Fortrea’s global clinical development expertise could help international sponsors identify relevant patient populations, plan trials more effectively and support targeted recruitment.
Fortrea said its oncology expertise is supported by thousands of operational professionals and more than 50 oncology physicians on staff. The company also says it has three decades of experience across more than 20 therapeutic areas, and its team works in about 100 countries. Fortrea trades on Nasdaq under the ticker FTRE.
Oct. 22, 2026.
